The full report suite is an extensive market analysis study on the current biologics such as ORENCIA, HUMIRA, CIMZIA, Enbrel, SIMPONI, REMICADE, RITUXAN, Actemra, STELARA, ENTYVIO and TYSABRI . The others segment includes XELJANZ, promising biologics in pipeline consisting of JAK inhibitors (imposing competition to XELJANZ) and other TNF and interleukin biologics that will enter the market during the forecast period.
Some of these biologics are approved and used in more than one conditions. Therefore, the market is segmented by diseases. The report comprises market analyses on rheumatoid arthritis, ankylosing spondylitis, Crohn`s disease, ulcerative colitis and psoriasis drugs globally.
The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases.
Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. The reports covers second line treatments, their dosage, comparative cost studies, market size and revenue forecasts.